Presenting at Next-Gen Immuno-Oncology Conference
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your SCLP notes
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that it will be presenting at the Next-Gen Immuno-Oncology Conference. The conference is being held from 7-8 March 2024 in London, UK.
Professor Lindy Durrant, Chief Executive Officer of Scancell, will be speaking at the "New Antibody Formats & Cell Therapy" session titled "A novel redirecting antibody targeting SCLC" which will take place from 2:45 pm - 3:15 pm GMT on Thursday 7 March 2024.
Professor Lindy Durrant, Chief Executive Officer of Scancell, said: "I am looking forward to presenting our preclinical results showing strong anti-tumour killing with no associated toxicity with our innovative T cell redirecting antibody at this premier event which is dedicated to advancing the field of immuno-oncology".
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.